Biophytis S.A.
Research Biophytis S.A. (ALBPS) on Bullrun: market cap EUR 1.40M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerALBPS
- ExchangePA
- CountryFrance
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 1.40M
- Financial periodFY2024
- Free cash flow-EUR 8.64M
Valuation Snapshot
latest market cap is EUR 1.40M.
About Biophytis S.A.
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients with age-related diseases. The company's lead drug candidate is the BIO101 to treat obesity, respiratory infections due to Covid-19, sarcopenia, and Duchenne Muscular Dystrophy (DMD). It has a collaboration agreement with AFM-Telethon for the development of its BIO101 for the treatment of DMD.
Frequently asked questions
What is Biophytis S.A.'s market cap?
Biophytis S.A.'s market capitalization is EUR 1.40M.
What does Biophytis S.A. do?
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients with age-related diseases.